CMS will discontinue the Part D Premium Stabilization Demonstration at the end of calendar year 2026, returning the Medicare drug benefit to traditional market conditions in 2027. The announcement came via the agency's July 28, 2026 fact sheet on 2027 Part D bid parameters, confirming the wind-down of a temporary authority CMS used to damp premium volatility during the transition triggered by the Inflation Reduction Act's Part D redesign.

The demonstration's 2026 parameters, finalized a year earlier in CMS's July 28, 2025 Parts C and D announcement, already showed a deliberate tightening from the program's inaugural 2025 cycle. CMS reduced the uniform base beneficiary premium reduction from $15 to $10. At the same time, the agency raised the cap on how much a plan's total Part D premium could grow year over year, permitting up to $35 in increases under the demonstration's guardrails. The 2026 demonstration also narrowed risk corridors — the range within which plans share gains and losses with the federal government — relative to the prior year.

Think of those 2026 design choices as a dial: CMS traded a thinner direct premium subsidy for more headroom on premium growth. Whether that calibration was the right call is a question the 2027 baseline will help answer, once the demonstration's dampening effect is fully removed and plans bid against their actual claims expectations without a federal backstop.

The 2026 Part D national average monthly bid amount stands at $239.27, per the annual bid information release published July 28, 2025. The Part D base beneficiary premium for 2026 is $38.99, and the de minimis amount — the threshold below which a plan doesn't have to charge the full base premium — is $2.00.

CMS projected in September 2025 that the average stand-alone Part D plan total premium would fall from $38.31 in 2025 to $34.50 in 2026, a decline of $3.81. That projection includes the demonstration's premium-reduction effect; the underlying bid economics without the $10 beneficiary premium reduction would produce a different headline figure. The gap between the $239.27 national average monthly bid and the $34.50 projected average total premium is bridged by the Part D premium-subtraction mechanism and reinsurance subsidies built into the redesigned benefit.

Looking at the transition ahead, the return to traditional market conditions in 2027 removes two structural supports at once: the cap on premium increases and the federal subsidy that directly reduces beneficiary premiums. Plans will reprice to claims risk without the demonstration's guardrails, and enrollees will see premiums that more directly reflect plan bid economics. The risk-corridor narrowing already signaled CMS's intent to wean plans off federal risk-sharing; full withdrawal in 2027 completes that trajectory.

For sponsors, the 2027 bid cycle will be the first clean read on plan pricing behavior under the IRA redesign without the demonstration overlay. For beneficiaries, the $34.50 average premium projected for 2026 may not be a reliable anchor once the $10 reduction and the $35 increase cap both lapse. The direction and magnitude of the move will depend on claims experience in the redesigned benefit's first full years of operation, pharmacy rebate dynamics, and the competitive response among stand-alone PDP and MA-PD sponsors.

The broader context here is that the Part D redesign under the IRA substantially shifted liability for catastrophic-phase spending onto plan sponsors. The demonstration was CMS's instrument for managing that transition. Its retirement implies the agency's judgment that the market can now absorb that liability without a federal stabilization mechanism. That is a judgment call, not a certainty, and 2027 bid submissions will be the first concrete test.